Vitamin B6, Inflammation, and Cardiovascular Outcome in a Population-Based Cohort: The Prevention of Renal and Vascular End-Stage Disease (PREVEND) Study
Background: a large number of studies have linked vitamin B6 to inflammation and cardiovascular disease in the general population. However, it remains uncertain whether vitamin B6 is associated with cardiovascular outcome independent of inflammation. Methods: we measured plasma pyridoxal 5’-phosphat...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-09-01
|
| Series: | Nutrients |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6643/12/9/2711 |
| _version_ | 1797554602724294656 |
|---|---|
| author | Isidor Minović Lyanne M. Kieneker Ron T. Gansevoort Manfred Eggersdorfer Daan J. Touw Albert-Jan Voerman Margery A. Connelly Rudolf A. de Boer Eelko Hak Jens Bos Robin P. F. Dullaart Ido P. Kema Stephan J. L. Bakker |
| author_facet | Isidor Minović Lyanne M. Kieneker Ron T. Gansevoort Manfred Eggersdorfer Daan J. Touw Albert-Jan Voerman Margery A. Connelly Rudolf A. de Boer Eelko Hak Jens Bos Robin P. F. Dullaart Ido P. Kema Stephan J. L. Bakker |
| author_sort | Isidor Minović |
| collection | DOAJ |
| description | Background: a large number of studies have linked vitamin B6 to inflammation and cardiovascular disease in the general population. However, it remains uncertain whether vitamin B6 is associated with cardiovascular outcome independent of inflammation. Methods: we measured plasma pyridoxal 5’-phosphate (PLP), as an indicator of vitamin B6 status, at baseline in a population-based prospective cohort of 6249 participants of the Prevention of Renal and Vascular End-stage Disease (PREVEND) study who were free of cardiovascular disease. As indicators of low-grade systemic inflammation, we measured high-sensitivity C-reactive protein and GlycA; Results: median plasma PLP was 37.2 (interquartile range, 25.1–57.0) nmol/L. During median follow-up for 8.3 (interquartile range, 7.8–8.9) years, 409 non-fatal and fatal cardiovascular events (composite outcome) occurred. In the overall cohort, log transformed plasma PLP was associated with the composite outcome, independent of adjustment for age, sex, smoking, alcohol consumption, body mass index (BMI), estimated glomerular filtration rate (eGFR), total cholesterol:high-density lipoprotein (HDL)-cholesterol ratio, and blood pressure (adjusted hazard ratio per increment of log plasma PLP, 0.66; 95% confidence interval (CI), 0.47–0.93). However, adjustment for high-sensitivity C-reactive protein and GlycA increased the hazard ratio by 9% and 12% respectively, to non-significant hazard ratios of 0.72 (95% confidence interval, 0.51–1.01) and 0.74 (95% confidence interval, 0.53–1.05). The association of plasma PLP with cardiovascular risk was modified by gender (adjusted P<sub>interaction</sub> = 0.04). When stratified according to gender, in women the prospective association with cardiovascular outcome was independent of age, smoking, alcohol consumption, high-sensitivity C-reactive protein, and GlycA (adjusted hazard ratio, 0.50, 95% confidence interval, 0.27–0.94), while it was not in men (adjusted hazard, 0.99, 95% confidence interval, 0.65–1.51). Conclusions: in this population-based cohort, plasma PLP was associated with cardiovascular outcome, but this association was confounded by traditional risk factors and parameters of inflammation. Notably, the association of low plasma PLP with high risk of adverse cardiovascular outcome was modified by gender, with a stronger and independent association in women. |
| first_indexed | 2024-03-10T16:34:26Z |
| format | Article |
| id | doaj.art-f14ed925c83845dcb91b6dae9b128414 |
| institution | Directory Open Access Journal |
| issn | 2072-6643 |
| language | English |
| last_indexed | 2024-03-10T16:34:26Z |
| publishDate | 2020-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Nutrients |
| spelling | doaj.art-f14ed925c83845dcb91b6dae9b1284142023-11-20T12:38:39ZengMDPI AGNutrients2072-66432020-09-01129271110.3390/nu12092711Vitamin B6, Inflammation, and Cardiovascular Outcome in a Population-Based Cohort: The Prevention of Renal and Vascular End-Stage Disease (PREVEND) StudyIsidor Minović0Lyanne M. Kieneker1Ron T. Gansevoort2Manfred Eggersdorfer3Daan J. Touw4Albert-Jan Voerman5Margery A. Connelly6Rudolf A. de Boer7Eelko Hak8Jens Bos9Robin P. F. Dullaart10Ido P. Kema11Stephan J. L. Bakker12Department of Laboratory Medicine, University of Groningen, University Medical Center Groningen, 9700RB Groningen, The NetherlandsDepartment of Internal Medicine, University of Groningen, University Medical Center Groningen, 9700RB Groningen, The NetherlandsDepartment of Internal Medicine, University of Groningen, University Medical Center Groningen, 9700RB Groningen, The NetherlandsDSM Nutritional Products, CH-4303 Kaiseraugst, SwitzerlandDepartment of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, 9700RB Groningen, The NetherlandsDepartment of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, 9700RB Groningen, The NetherlandsLaboratory Corporation of America® Holdings (LabCorp), Morrisville, NC 27560, USADepartment of Cardiology, University of Groningen, University Medical Center Groningen, 9700RB Groningen, The NetherlandsUnit of Pharmacotherapy, Epidemiology and Economics, University of Groningen, 9712CP Groningen, The NetherlandsUnit of Pharmacotherapy, Epidemiology and Economics, University of Groningen, 9712CP Groningen, The NetherlandsDepartment of Internal Medicine, University of Groningen, University Medical Center Groningen, 9700RB Groningen, The NetherlandsDepartment of Laboratory Medicine, University of Groningen, University Medical Center Groningen, 9700RB Groningen, The NetherlandsDepartment of Internal Medicine, University of Groningen, University Medical Center Groningen, 9700RB Groningen, The NetherlandsBackground: a large number of studies have linked vitamin B6 to inflammation and cardiovascular disease in the general population. However, it remains uncertain whether vitamin B6 is associated with cardiovascular outcome independent of inflammation. Methods: we measured plasma pyridoxal 5’-phosphate (PLP), as an indicator of vitamin B6 status, at baseline in a population-based prospective cohort of 6249 participants of the Prevention of Renal and Vascular End-stage Disease (PREVEND) study who were free of cardiovascular disease. As indicators of low-grade systemic inflammation, we measured high-sensitivity C-reactive protein and GlycA; Results: median plasma PLP was 37.2 (interquartile range, 25.1–57.0) nmol/L. During median follow-up for 8.3 (interquartile range, 7.8–8.9) years, 409 non-fatal and fatal cardiovascular events (composite outcome) occurred. In the overall cohort, log transformed plasma PLP was associated with the composite outcome, independent of adjustment for age, sex, smoking, alcohol consumption, body mass index (BMI), estimated glomerular filtration rate (eGFR), total cholesterol:high-density lipoprotein (HDL)-cholesterol ratio, and blood pressure (adjusted hazard ratio per increment of log plasma PLP, 0.66; 95% confidence interval (CI), 0.47–0.93). However, adjustment for high-sensitivity C-reactive protein and GlycA increased the hazard ratio by 9% and 12% respectively, to non-significant hazard ratios of 0.72 (95% confidence interval, 0.51–1.01) and 0.74 (95% confidence interval, 0.53–1.05). The association of plasma PLP with cardiovascular risk was modified by gender (adjusted P<sub>interaction</sub> = 0.04). When stratified according to gender, in women the prospective association with cardiovascular outcome was independent of age, smoking, alcohol consumption, high-sensitivity C-reactive protein, and GlycA (adjusted hazard ratio, 0.50, 95% confidence interval, 0.27–0.94), while it was not in men (adjusted hazard, 0.99, 95% confidence interval, 0.65–1.51). Conclusions: in this population-based cohort, plasma PLP was associated with cardiovascular outcome, but this association was confounded by traditional risk factors and parameters of inflammation. Notably, the association of low plasma PLP with high risk of adverse cardiovascular outcome was modified by gender, with a stronger and independent association in women.https://www.mdpi.com/2072-6643/12/9/2711vitamin B6pyridoxal 5’-phosphateinflammationGlycAcardiovascular |
| spellingShingle | Isidor Minović Lyanne M. Kieneker Ron T. Gansevoort Manfred Eggersdorfer Daan J. Touw Albert-Jan Voerman Margery A. Connelly Rudolf A. de Boer Eelko Hak Jens Bos Robin P. F. Dullaart Ido P. Kema Stephan J. L. Bakker Vitamin B6, Inflammation, and Cardiovascular Outcome in a Population-Based Cohort: The Prevention of Renal and Vascular End-Stage Disease (PREVEND) Study Nutrients vitamin B6 pyridoxal 5’-phosphate inflammation GlycA cardiovascular |
| title | Vitamin B6, Inflammation, and Cardiovascular Outcome in a Population-Based Cohort: The Prevention of Renal and Vascular End-Stage Disease (PREVEND) Study |
| title_full | Vitamin B6, Inflammation, and Cardiovascular Outcome in a Population-Based Cohort: The Prevention of Renal and Vascular End-Stage Disease (PREVEND) Study |
| title_fullStr | Vitamin B6, Inflammation, and Cardiovascular Outcome in a Population-Based Cohort: The Prevention of Renal and Vascular End-Stage Disease (PREVEND) Study |
| title_full_unstemmed | Vitamin B6, Inflammation, and Cardiovascular Outcome in a Population-Based Cohort: The Prevention of Renal and Vascular End-Stage Disease (PREVEND) Study |
| title_short | Vitamin B6, Inflammation, and Cardiovascular Outcome in a Population-Based Cohort: The Prevention of Renal and Vascular End-Stage Disease (PREVEND) Study |
| title_sort | vitamin b6 inflammation and cardiovascular outcome in a population based cohort the prevention of renal and vascular end stage disease prevend study |
| topic | vitamin B6 pyridoxal 5’-phosphate inflammation GlycA cardiovascular |
| url | https://www.mdpi.com/2072-6643/12/9/2711 |
| work_keys_str_mv | AT isidorminovic vitaminb6inflammationandcardiovascularoutcomeinapopulationbasedcohortthepreventionofrenalandvascularendstagediseaseprevendstudy AT lyannemkieneker vitaminb6inflammationandcardiovascularoutcomeinapopulationbasedcohortthepreventionofrenalandvascularendstagediseaseprevendstudy AT rontgansevoort vitaminb6inflammationandcardiovascularoutcomeinapopulationbasedcohortthepreventionofrenalandvascularendstagediseaseprevendstudy AT manfredeggersdorfer vitaminb6inflammationandcardiovascularoutcomeinapopulationbasedcohortthepreventionofrenalandvascularendstagediseaseprevendstudy AT daanjtouw vitaminb6inflammationandcardiovascularoutcomeinapopulationbasedcohortthepreventionofrenalandvascularendstagediseaseprevendstudy AT albertjanvoerman vitaminb6inflammationandcardiovascularoutcomeinapopulationbasedcohortthepreventionofrenalandvascularendstagediseaseprevendstudy AT margeryaconnelly vitaminb6inflammationandcardiovascularoutcomeinapopulationbasedcohortthepreventionofrenalandvascularendstagediseaseprevendstudy AT rudolfadeboer vitaminb6inflammationandcardiovascularoutcomeinapopulationbasedcohortthepreventionofrenalandvascularendstagediseaseprevendstudy AT eelkohak vitaminb6inflammationandcardiovascularoutcomeinapopulationbasedcohortthepreventionofrenalandvascularendstagediseaseprevendstudy AT jensbos vitaminb6inflammationandcardiovascularoutcomeinapopulationbasedcohortthepreventionofrenalandvascularendstagediseaseprevendstudy AT robinpfdullaart vitaminb6inflammationandcardiovascularoutcomeinapopulationbasedcohortthepreventionofrenalandvascularendstagediseaseprevendstudy AT idopkema vitaminb6inflammationandcardiovascularoutcomeinapopulationbasedcohortthepreventionofrenalandvascularendstagediseaseprevendstudy AT stephanjlbakker vitaminb6inflammationandcardiovascularoutcomeinapopulationbasedcohortthepreventionofrenalandvascularendstagediseaseprevendstudy |